Revvity, Inc. (RVTY) to Distribute Quarterly Dividend of $0.07 on August 9th

Revvity, Inc. (NYSE:RVTY) announced a quarterly dividend on Thursday, April 25th, RTT News reports. Investors of record on Friday, July 19th will be given a dividend of 0.07 per share on Friday, August 9th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%.

Revvity has a payout ratio of 5.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Revvity to earn $5.20 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 5.4%.

Revvity Price Performance

Revvity stock opened at $101.51 on Friday. Revvity has a 1 year low of $79.50 and a 1 year high of $132.54. The firm has a 50 day moving average price of $104.66 and a 200 day moving average price of $101.46. The company has a market cap of $12.54 billion, a price-to-earnings ratio of 18.46, a PEG ratio of 2.66 and a beta of 1.09. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.77 and a current ratio of 2.07.

Revvity (NYSE:RVTY) last released its earnings results on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The firm had revenue of $695.90 million during the quarter. Sell-side analysts predict that Revvity will post 4.65 earnings per share for the current year.

Insider Transactions at Revvity

In other news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the transaction, the insider now directly owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on RVTY shares. Evercore ISI upgraded shares of Revvity from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $88.00 to $125.00 in a research note on Thursday, January 4th. UBS Group downgraded shares of Revvity from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $105.00 to $125.00 in a research note on Tuesday, January 16th. Barclays boosted their price objective on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. KeyCorp boosted their price objective on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Finally, Raymond James boosted their price objective on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.91.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.